Finance

Lists
Outlook: 76.9% bullish·3.9% bearish
Go to analysis
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
$337.97
-0.87%
(-2.95) 1D
$337.97
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
$342.18
High
$342.58
Low
$333.04
Mkt. cap
16.19B
Avg. vol.
1.19M
Volume
838.32K
P/E ratio
374.61
52-wk high
$379.63
52-wk low
$146.20
EPS
$0.90
Beta
1.36
Shares outstanding
47.92M
No. of employees
19K
Open
$342.18
High
$342.58
Low
$333.04
Mkt. cap
16.19B
Avg. vol.
1.19M
Volume
838.32K
P/E ratio
374.61
52-wk high
$379.63
52-wk low
$146.20
EPS
$0.90
Beta
1.36
Shares outstanding
47.92M
No. of employees
19K
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19K
Founded1947
HeadquartersWilmington, Massachusetts, United States
SectorHealth Care
Industry-
Websitecriver.com
Analyst ratings
Based on 15 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current $337.97
$400.00 (+18.35%)
Average
$355.08 (+5.06%)
Lowest
$315.00 (-6.80%)
Analyst
Recommendation
Action
Price target
Projected
Date
Charles Rhyee
TD Cowen
Buy
Maintained
$388.00
+14.8%
11/11/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$385.00
+13.9%
11/05/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
$315.00
-6.8%
11/06/2026
‏Avantika Dhabaria‏
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
Kevin Caliendo
UBS
Buy
Reiterated
$387.00
+14.5%
11/05/2026
Ryan Halsted
RBC Capital
Buy
Reiterated
$352.00
+4.2%
11/04/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$364.00
+7.7%
11/05/2026
Luke Sergott
Barclays
Buy
Maintained
$375.00
+11%
11/05/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$400.00
+18.4%
11/04/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
$340.00
+0.6%
10/13/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
$340.00
+0.6%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
$320.00
-5.3%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
$320.00
-5.3%
09/22/2026
David Toung
Argus Research
Buy
Reiterated
$330.00
-2.4%
09/16/2026
Michael Luo CFA
CLSA
Hold
Downgraded
$219.00
-35.2%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
$265.00
-21.6%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
$215.00
-36.4%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
$175.00
-48.2%
02/25/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$3.09 / $2.98
+3.55%beat
Revenue / Est. (USD)
982.73M / 960.36M
+2.33%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
994.23M
995.83M
1.00B
982.73M
Cost of goods sold
665.36M
672.79M
625.06M
617.83M
Cost of revenue
665.36M
672.79M
625.06M
617.83M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
192.02M
149.12M
214.18M
126.01M
Operating expense
284.04M
164.46M
227.27M
134.75M
Total operating expenses
949.40M
837.25M
852.33M
752.58M
Operating income
44.83M
158.58M
151.74M
230.15M
Other non operating income
27.72M
-123.11M
25.99M
-3.31M
EBT including unusual items
-294.10M
-29.94M
53.17M
170.66M
EBT excluding unusual items
35.18M
8.62M
148.43M
197.07M
Income tax expense
-17.81M
-15.14M
53.93M
-163.79M
Effective tax rate
6.06%
50.56%
101.43%
-95.97%
Other operating expenses
-
-
-
-
Net income
-276.56M
-14.84M
-1.48M
333.07M
Net profit margin
-27.82%
-1.49%
-0.15%
33.89%
Earnings per share
2.39
2.06
3.02
3.09
Interest and investment income
1.02M
1.03M
1.03M
958.00K
Interest expense
-23.78M
-26.74M
-30.34M
-28.52M
Net interest expenses
-22.76M
-25.71M
-29.31M
-27.57M
Depreciation and amortization charges
-
-
-
-
EBITDA
169.61M
225.73M
217.54M
296.51M
Gain or loss from assets sale
-
117.98M
24.92M
-378.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps